Drugs / VRC-EBOADC076-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02231866 | Aug 2014 → Apr 2017 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-EBOADC076-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02231866 ↗ |
| Known as | cAd3-EBOZ | “VRC-EBOADC076-00-VP (cAd3-EBOZ) is composed of a cAd3 vector that expresses Ebola WT GP from the Zaire strain.” NCT02231866 ↗ |
| Route | Intramuscular | “administered as single intramuscular (IM) injections” NCT02231866 ↗ |